Intraperitoneal cisplatin-based chemotherapy versus intravenous cisplatin-based chemotherapy for stage III ovarian cancer with minimal residual disease: 10 years experience

A retrospective study was conducted to compare the survival between intraperitoneal cisplatin-based chemotherapy (IPCT) and intravenous cisplatin-based chemotherapy (IVCT) in stage III epithelial ovarian cancer with minimal residual disease (<1cm) after primary debulking surgery during year 1985-1996. Of 114 patients, 89 patients were eligible into the study (47 in the intravenous group and 42 in the intraperitoneal group). The estimated median survival in the IPCT group was 43 months (95% CI, 33 to 54) and IVCT group was 48 months (95% CI, 37 to 59), P=0.6125. The hazard ratio of death was also not statistically significant between IPCT and IVCT (hazard ration, 1.13; 95% CI, 0.69 to 1.86; P=0.6153). The prevalence of hematological toxic effects was significantly lower in the IPCT group.